{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:27:47Z","timestamp":1790879267374,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9,15]]},"DOI":"10.1093\/hmg\/ddr288","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T22:01:52Z","timestamp":1308693712000},"page":"3667-3677","source":"Crossref","is-referenced-by-count":59,"title":["Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice"],"prefix":"10.1093","volume":"20","author":[{"given":"Deborah Y.","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Motley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Fischbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrington G.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,6,21]]},"reference":[{"key":"key\n\t\t\t\t20170522124112_DDR288C1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/71709","article-title":"A mouse model for spinal muscular atrophy","volume":"24","author":"Hsieh-Li","year":"2000","journal-title":"Nat. Genet."},{"key":"key\n\t\t\t\t20170522124112_DDR288C2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170522124112_DDR288C3","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1086\/515465","article-title":"Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number","volume":"60","author":"McAndrew","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"key\n\t\t\t\t20170522124112_DDR288C4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ajmg.a.30251","article-title":"Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2","volume":"130","author":"Prior","year":"2004","journal-title":"Am. J. Med. Genet. A"},{"key":"key\n\t\t\t\t20170522124112_DDR288C5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1128\/MCB.01262-08","article-title":"Regulation of SMN Protein Stability","volume":"29","author":"Burnett","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"key\n\t\t\t\t20170522124112_DDR288C6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.neuint.2004.04.005","article-title":"Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin\/proteasome pathway","volume":"45","author":"Chang","year":"2004","journal-title":"Neurochem. Int."},{"key":"key\n\t\t\t\t20170522124112_DDR288C7","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1074\/jbc.M509043200","article-title":"Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate","volume":"281","author":"Kisselev","year":"2006","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170522124112_DDR288C8","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res."},{"key":"key\n\t\t\t\t20170522124112_DDR288C9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","article-title":"Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy","volume":"117","author":"Avila","year":"2007","journal-title":"J. Clin. Invest."},{"key":"key\n\t\t\t\t20170522124112_DDR288C10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ana.21449","article-title":"Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition","volume":"64","author":"Narver","year":"2008","journal-title":"Ann. Neurol."},{"key":"key\n\t\t\t\t20170522124112_DDR288C11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/hmg\/ddg157","article-title":"Neuromuscular defects in a Drosophila survival motor neuron gene mutant","volume":"12","author":"Chan","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t20170522124112_DDR288C12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1083\/jcb.152.5.1107","article-title":"Deletion of murine SMN exon 7 directed to skeletal muscle leads to severe muscular dystrophy","volume":"152","author":"Cifuentes-Diaz","year":"2001","journal-title":"J. Cell Biol."},{"key":"key\n\t\t\t\t20170522124112_DDR288C13","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/hmg\/ddm379","article-title":"Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect","volume":"17","author":"Gavrilina","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t20170522124112_DDR288C14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/hmg\/ddn426","article-title":"Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy","volume":"18","author":"Rose","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t20170522124112_DDR288C15","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1093\/hmg\/ddp253","article-title":"Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice","volume":"18","author":"Sumner","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t20170522124112_DDR288C16","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1093\/hmg\/ddp313","article-title":"LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate","volume":"18","author":"Garbes","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t20170522124112_DDR288C17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/hmg\/ddi078","article-title":"SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN","volume":"14","author":"Le","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t20170522124112_DDR288C18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jnr.490420104","article-title":"Expression of neurotrophins in skeletal muscle: quantitative comparison and significance for motoneuron survival and maintenance of function","volume":"42","author":"Griesbeck","year":"1995","journal-title":"J. Neurosci. Res."},{"key":"key\n\t\t\t\t20170522124112_DDR288C19","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/0896-6273(92)90213-W","article-title":"The neurotrophins BDNF, NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons","volume":"8","author":"DiStefano","year":"1992","journal-title":"Neuron"},{"key":"key\n\t\t\t\t20170522124112_DDR288C20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuron.2009.07.019","article-title":"Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy","volume":"63","author":"Palazzolo","year":"2009","journal-title":"Neuron"},{"key":"key\n\t\t\t\t20170522124112_DDR288C21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0896-6273(93)90182-Q","article-title":"The Drosophila bendless gene encodes a neural protein related to ubiquitin-conjugating enzymes","volume":"11","author":"Muralidhar","year":"1993","journal-title":"Neuron"},{"key":"key\n\t\t\t\t20170522124112_DDR288C22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2007.08.005","article-title":"The ubiquitin-proteasome pathway in health and disease of the nervous system","volume":"30","author":"Hegde","year":"2007","journal-title":"Trends Neurosci."},{"key":"key\n\t\t\t\t20170522124112_DDR288C23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1124\/pr.59.1.4","article-title":"Emerging roles for ubiquitin and protein degradation in neuronal function","volume":"59","author":"Yi","year":"2007","journal-title":"Pharmacol. Rev."},{"key":"key\n\t\t\t\t20170522124112_DDR288C24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0092-8674(02)01012-7","article-title":"The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility","volume":"111","author":"Liu","year":"2002","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170522124112_DDR288C25","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1128\/MCB.19.2.1182","article-title":"The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily","volume":"19","author":"Nawaz","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"key\n\t\t\t\t20170522124112_DDR288C26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ng762","article-title":"MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation","volume":"29","author":"Trockenbacher","year":"2001","journal-title":"Nat. Genet."},{"key":"key\n\t\t\t\t20170522124112_DDR288C27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ajhg.2007.09.009","article-title":"Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy","volume":"82","author":"Ramser","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"key\n\t\t\t\t20170522124112_DDR288C28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.neuro.22.1.389","article-title":"Development of the vertebrate neuromuscular junction","volume":"22","author":"Sanes","year":"1999","journal-title":"Annu. Rev. Neurosci."},{"key":"key\n\t\t\t\t20170522124112_DDR288C29","doi-asserted-by":"crossref","first-page":"10909","DOI":"10.1523\/JNEUROSCI.2635-09.2009","article-title":"The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions","volume":"29","author":"Chen","year":"2009","journal-title":"J. Neurosci."},{"key":"key\n\t\t\t\t20170522124112_DDR288C30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.mam.2009.04.001","article-title":"The proteasomal system","volume":"30","author":"Jung","year":"2009","journal-title":"Mol. Aspects Med."},{"key":"key\n\t\t\t\t20170522124112_DDR288C31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/med.20111","article-title":"Proteasome inhibitors: poisons and remedies","volume":"28","author":"Meiners","year":"2008","journal-title":"Med. Res. Rev."},{"key":"key\n\t\t\t\t20170522124112_DDR288C32","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0002-9440(10)63523-7","article-title":"Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins","volume":"163","author":"Bonuccelli","year":"2003","journal-title":"Am. J. Pathol."},{"key":"key\n\t\t\t\t20170522124112_DDR288C33","doi-asserted-by":"crossref","first-page":"C577","DOI":"10.1152\/ajpcell.00434.2005","article-title":"Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment","volume":"290","author":"Assereto","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"key\n\t\t\t\t20170522124112_DDR288C34","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.4161\/cc.6.10.4182","article-title":"Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice","volume":"6","author":"Bonuccelli","year":"2007","journal-title":"Cell Cycle"},{"key":"key\n\t\t\t\t20170522124112_DDR288C35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1634\/theoncologist.12-3-281","article-title":"The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib","volume":"12","author":"Armand","year":"2007","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20170522124112_DDR288C36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2004.07.165","article-title":"Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study","volume":"22","author":"Davis","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"key\n\t\t\t\t20170522124112_DDR288C37","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cncr.22097","article-title":"Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia","volume":"107","author":"Faderl","year":"2006","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20170522124112_DDR288C38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2404444","article-title":"Proteasome inhibitors: antitumor effects and beyond","volume":"21","author":"Nencioni","year":"2007","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170522124112_DDR288C39","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1200\/JCO.2004.12.185","article-title":"Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015)","volume":"22","author":"Blaney","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"key\n\t\t\t\t20170522124112_DDR288C40","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/1078-0432.CCR-06-2173","article-title":"A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study","volume":"13","author":"Horton","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"key\n\t\t\t\t20170522124112_DDR288C41","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in SMN gene expression","volume":"14","author":"Kernochan","year":"2005","journal-title":"Hum. Mol. Genet."}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/20\/18\/3667\/17253571\/ddr288.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:10:59Z","timestamp":1503447059000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article-lookup\/doi\/10.1093\/hmg\/ddr288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,21]]},"references-count":41,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2011,6,21]]},"published-print":{"date-parts":[[2011,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddr288","relation":{},"ISSN":["1460-2083","0964-6906"],"issn-type":[{"value":"1460-2083","type":"electronic"},{"value":"0964-6906","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6,21]]}}}